XML 38 R30.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stockholders' Equity (Tables)
3 Months Ended
Dec. 31, 2024
Stockholders' Equity Note [Abstract]  
Schedule of stockholders' equity

The changes in stockholders’ equity for the prior year comparable period are as follows:

 

 

 

 

 

 

Additional

 

 

 

 

 

Accumulated
Other

 

 

 

 

 

 

Common Stock

 

Paid-in

 

Treasury Stock

 

Comprehensive

 

Retained

 

 

 

 

Shares

 

Amount

 

Capital

 

Shares

 

Amount

 

Loss

 

Earnings

 

Total

 

Balance at September 30, 2023

 

36,142,345

 

$

36

 

$

265,945

 

 

(5,433,045

)

$

(84,031

)

$

(10,458

)

$

(9,958

)

$

161,533

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

1,907

 

 

1,907

 

Exercise of stock options, grants of restricted stock awards, and vesting of restricted stock units

 

59,471

 

 

 

 

127

 

 

 

 

 

 

 

 

 

 

127

 

Taxes paid associated with net settlement of stock compensation awards

 

(12,058

)

 

 

 

(224

)

 

 

 

 

 

 

 

 

 

(224

)

Common stock repurchased

 

 

 

 

 

 

 

(68,692

)

 

(1,171

)

 

 

 

 

 

(1,171

)

Stock compensation expense

 

 

 

 

 

2,249

 

 

 

 

 

 

 

 

 

 

2,249

 

Foreign currency translation and other

 

 

 

 

 

 

 

 

 

 

 

958

 

 

 

 

958

 

Balance at December 31, 2023

 

36,189,758

 

$

36

 

$

268,096

 

 

(5,501,737

)

$

(85,202

)

$

(9,500

)

$

(8,051

)

$

165,379

 

Summary of share-based compensation expense

The table below presents the components of share-based compensation expense (in thousands):

 

 

 

Three Months Ended December 31,

 

 

 

2024

 

 

2023

 

Equity-classified awards:

 

 

 

 

 

 

Stock options

 

$

659

 

 

$

500

 

RSUs & RSAs

 

 

2,772

 

 

 

1,749

 

Total Equity-classified award

 

 

3,431

 

 

 

2,249

 

Liability-classified awards:

 

 

 

 

 

 

SARs

 

 

 

 

 

 

Total stock compensation expense:

 

$

3,431

 

 

$

2,249

 

The table below presents the components of share-based compensation expense by line-item within our Condensed Consolidated Statements of Operations (in thousands):

 

 

 

Three Months Ended December 31,

 

 

 

2024

 

 

2023

 

Stock-compensation expense by function

 

 

 

 

 

 

Technology and operations

 

$

551

 

 

$

330

 

Sales and marketing

 

 

1,021

 

 

 

638

 

General and administrative

 

 

1,859

 

 

 

1,281

 

Total stock compensation expense:

 

$

3,431

 

 

$

2,249

 

Summary of stock options and restricted stock granted

The following table presents stock option and RSUs & RSAs grant activity:

 



 

Three Months Ended December 31, 2024

 

Stock Options granted:

 



 

Options containing only service conditions:

 

 

125,000

 

Weighted average exercise price

 

$

22.55

 

Weighted average grant date fair value

 

$

10.86

 



 



 

Options containing performance conditions:

 

 

125,000

 

Weighted average exercise price

 

$

22.55

 

Weighted average grant date fair value

 

$

10.86

 



 



 

RSUs & RSAs granted:

 



 

RSUs & RSAs containing only service conditions:

 

 

304,519

 

Weighted average grant date fair value

 

$

23.55

 



 



 

RSUs & RSAs containing performance conditions:

 

 

304,521

 

Weighted average grant date fair value

 

$

23.55

 

Summary of fair value assumptions, stock options

The range of assumptions used to determine the fair value of stock options using the Black-Scholes option-pricing model during the three months ended December 31, 2024, were as follows:

 

 

 

Three Months Ended

 

 

 

December 31, 2024

 

Dividend yield

 

 

 

Expected volatility

 

56.09% - 57.96%

 

Risk-free interest rate

 

4.10% - 4.10%

 

Expected term

 

4.4 - 5.0 years